top of page
© 2025 Eradicus. All rights resrved.
Mission 03: TB Eradication
Make Next-Generation Rapid Molecular Testing for Tuberculosis Easily Accessible to Over 1 Billion Indians.
Mission Timeline:
December 2022 to Ongoing
Mission Status: Regulatory Review
Why Tuberculosis?
Tuberculosis (TB) remains a significant public health concern in India. According to the National Tuberculosis Elimination Programme, the estimated TB incidence in India for 2022 was 2.82 million new cases. Mortality from TB was estimated to be 331,000 deaths in 2022.
​
A large burden of TB care is placed on the public sector in India, with approximately 67% of cases being reported by the public sector and only 33% by the private sector.
The Indian government has set an ambitious goal to eliminate TB by 2025, five years ahead of the global target. Achieving this objective will require sustained efforts in early detection, effective treatment, and addressing social determinants that contribute to TB transmission.
Our solution can detect mTB DNA and Drug Resistance in under 20 minutes.
Our proprietary next-generation rapid molecular chemistry enables us to detect TB DNA and to detect drug resistance related mutations in under 20 minutes.
Visit us again in Q2 of 2025 for updates on our technology and mission status.
bottom of page